Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will release its second-quarter 2025 financial results tomorrow, July 30.

According to Benzinga Pro, the company expects to report second-quarter earnings of 62 cents, with sales of around $4.29 billion.

Teva’s generics business has rebounded. The company saw a 5% increase in revenue across regions. Its top-three global portfolio may yield five new product launches by 2027.

Also Read: Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

According to Piper Sandler, generic Revlimid won't matter much to the business after this year due to rising competition. However, it still plays a vital role in the U.S. generics segment.

The company's management expects the first quarter of 2025 to show the strongest year-over-year growth for its generics business.

They also noted that they usually sell ...